S&P 500   5,072.85 (+0.22%)
DOW   37,937.90 (+0.54%)
QQQ   432.57 (+0.35%)
AAPL   169.67 (-1.75%)
MSFT   416.22 (+0.62%)
META   501.57 (+0.27%)
GOOGL   154.94 (+0.05%)
AMZN   183.81 (+0.10%)
TSLA   156.61 (-3.02%)
NVDA   877.45 (+2.03%)
AMD   163.57 (+2.03%)
NIO   3.85 (-1.03%)
BABA   69.96 (-0.93%)
T   16.04 (-1.23%)
F   12.18 (-0.41%)
MU   121.98 (+0.50%)
GE   156.75 (+1.98%)
CGC   6.80 (-2.58%)
DIS   114.03 (+0.96%)
AMC   2.78 (+12.55%)
PFE   25.80 (-0.42%)
PYPL   63.76 (+0.39%)
XOM   119.17 (-0.43%)
S&P 500   5,072.85 (+0.22%)
DOW   37,937.90 (+0.54%)
QQQ   432.57 (+0.35%)
AAPL   169.67 (-1.75%)
MSFT   416.22 (+0.62%)
META   501.57 (+0.27%)
GOOGL   154.94 (+0.05%)
AMZN   183.81 (+0.10%)
TSLA   156.61 (-3.02%)
NVDA   877.45 (+2.03%)
AMD   163.57 (+2.03%)
NIO   3.85 (-1.03%)
BABA   69.96 (-0.93%)
T   16.04 (-1.23%)
F   12.18 (-0.41%)
MU   121.98 (+0.50%)
GE   156.75 (+1.98%)
CGC   6.80 (-2.58%)
DIS   114.03 (+0.96%)
AMC   2.78 (+12.55%)
PFE   25.80 (-0.42%)
PYPL   63.76 (+0.39%)
XOM   119.17 (-0.43%)
S&P 500   5,072.85 (+0.22%)
DOW   37,937.90 (+0.54%)
QQQ   432.57 (+0.35%)
AAPL   169.67 (-1.75%)
MSFT   416.22 (+0.62%)
META   501.57 (+0.27%)
GOOGL   154.94 (+0.05%)
AMZN   183.81 (+0.10%)
TSLA   156.61 (-3.02%)
NVDA   877.45 (+2.03%)
AMD   163.57 (+2.03%)
NIO   3.85 (-1.03%)
BABA   69.96 (-0.93%)
T   16.04 (-1.23%)
F   12.18 (-0.41%)
MU   121.98 (+0.50%)
GE   156.75 (+1.98%)
CGC   6.80 (-2.58%)
DIS   114.03 (+0.96%)
AMC   2.78 (+12.55%)
PFE   25.80 (-0.42%)
PYPL   63.76 (+0.39%)
XOM   119.17 (-0.43%)
S&P 500   5,072.85 (+0.22%)
DOW   37,937.90 (+0.54%)
QQQ   432.57 (+0.35%)
AAPL   169.67 (-1.75%)
MSFT   416.22 (+0.62%)
META   501.57 (+0.27%)
GOOGL   154.94 (+0.05%)
AMZN   183.81 (+0.10%)
TSLA   156.61 (-3.02%)
NVDA   877.45 (+2.03%)
AMD   163.57 (+2.03%)
NIO   3.85 (-1.03%)
BABA   69.96 (-0.93%)
T   16.04 (-1.23%)
F   12.18 (-0.41%)
MU   121.98 (+0.50%)
GE   156.75 (+1.98%)
CGC   6.80 (-2.58%)
DIS   114.03 (+0.96%)
AMC   2.78 (+12.55%)
PFE   25.80 (-0.42%)
PYPL   63.76 (+0.39%)
XOM   119.17 (-0.43%)
Free Trial

Actinium Pharmaceuticals (ATNM) Stock Forecast & Price Target

→ Your eBook: Mastering Earnings Announcements Trading (From StockEarnings) (Ad)
Free ATNM Stock Alerts
$7.72
-0.72 (-8.53%)
(As of 03:19 PM ET)
Compare
Stock AnalysisAnalyst ForecastsChartEarningsHeadlinesOwnershipShort Interest

Actinium Pharmaceuticals Consensus Analyst Rating and Stock Price Forecast (2024)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Analysts' Consensus Rating

Buy
Based on 5 Analyst Ratings

Analysts' Consensus Price Target

$25.72
233.16% Upside
High Forecast$50.00
Average Forecast$25.72
Low Forecast$11.60
TypeCurrent Forecast
4/17/23 to 4/16/24		1 Month Ago
3/18/23 to 3/17/24		3 Months Ago
1/17/23 to 1/17/24		1 Year Ago
4/17/22 to 4/17/23
Consensus Rating
Buy
Buy
Moderate Buy
Moderate Buy
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
3 Buy rating(s)
Hold
0 Hold rating(s)
0 Hold rating(s)
1 Hold rating(s)
1 Hold rating(s)
Sell
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
0 Sell rating(s)
Consensus Price Target$25.72$26.15$26.15$33.25
Predicted Upside233.16% Upside301.95% Upside301.95% Upside201.72% Upside
Get Actinium Pharmaceuticals Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for ATNM and its competitors with MarketBeat's FREE daily newsletter.

ATNM Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

ATNM Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

Actinium Pharmaceuticals Stock vs. The Competition

TypeActinium PharmaceuticalsMedical CompaniesS&P 500
Consensus Rating Score
3.00
2.68
2.49
Consensus RatingBuyModerate BuyHold
Predicted Upside205.83% Upside881.90% Upside11.20% Upside
News Sentiment RatingNeutral News
Positive News
Positive News

Recent Analyst Ratings and Stock Forecasts

Export to Excel
DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
4/1/2024HC Wainwright
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingBuy ➝ Buy$50.00+483.43%
4/1/2024Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Reiterated RatingOverweight ➝ Overweight$21.00+170.97%
3/19/2024Maxim Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Boost TargetBuy ➝ Buy$20.00 ➝ $30.00+279.27%
12/11/2023B. Riley
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Lower TargetBuy ➝ Buy$20.00 ➝ $16.00+207.69%
9/6/2023HSBC
Subscribe to MarketBeat All Access for the recommendation accuracy rating		 Initiated CoverageBuy$11.60+77.64%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Tuesday at 03:37 PM ET.

ATNM Price Target - Frequently Asked Questions

What is Actinium Pharmaceuticals's consensus rating and price target?

According to the issued ratings of 5 analysts in the last year, the consensus rating for Actinium Pharmaceuticals stock is Buy based on the current 5 buy ratings for ATNM. The average twelve-month price prediction for Actinium Pharmaceuticals is $25.72 with a high price target of $50.00 and a low price target of $11.60. Learn more on ATNM's analyst rating history.

Do Wall Street analysts like Actinium Pharmaceuticals more than its competitors?

Analysts like Actinium Pharmaceuticals more than other Medical companies. The consensus rating for Actinium Pharmaceuticals is Buy while the average consensus rating for medical companies is Moderate Buy. Learn more on how ATNM compares to other companies.

Does Actinium Pharmaceuticals's stock price have much upside?

According to analysts, Actinium Pharmaceuticals's stock has a predicted upside of 257.62% based on their 12-month stock forecasts.

What analysts cover Actinium Pharmaceuticals?

Actinium Pharmaceuticals has been rated by Cantor Fitzgerald, HC Wainwright, and Maxim Group in the past 90 days.


Stock Ratings Reports and Tools

Related Companies:
Today's Ratings:
Top Rated Stocks:
More Ratings Tools:
This page (NYSEAMERICAN:ATNM) was last updated on 4/16/2024 by MarketBeat.com Staff

From Our Partners
Red Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!
Priority Gold
Can't believe it's happening again
Manward Press
He Is Giving Away Bitcoin
Crypto Swap Profits
This Apple-like Innovator is Revolutionizing Healthcare
Wall Street Star
Healthcare Takes A Big Step Forward With The Help Of AI
The Bull Report
Your eBook: Mastering Earnings Announcements Trading
StockEarnings
The "Smart Money" Is Ready for May 1st Are You?
Stansberry Research
Options trading has suddenly become more reliable.
Eagle Publishing